Product Code: SR112024A2039
The global next-generation sequencing (NGS) market size reached US$ 20.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 80.4 Billion by 2032, exhibiting a growth rate (CAGR) of 16.2% during 2024-2032.
Next-generation sequencing (NGS) is a parallel sequencing technology that determines the sequence of nucleotides in a section of the deoxyribonucleic acid (DNA). It involves various procedures, such as sequencing by synthesis (SBS) and ion semiconductor, single-molecule real-time (SMRT), and nanopore sequencing. It is a cost-effective solution that assists medical professionals in achieving precise results with high accuracy and speed. It also facilitates research in the fields of clinical diagnostics, personalized and genetic medicines, and agriculture and animal studies. At present, it is utilized in pharmacogenomics to escalate the drug delivery process.
Next-Generation Sequencing (NGS) Market Trends:
The growing global geriatric population and the rising prevalence of various chronic medical disorders, such as cancer, cardiovascular, and neurological disorders, represent one of the key factors positively influencing the market. It can also be attributed to the growing use of genetic maps for guiding scientists to analyze the genes that are responsible for medical conditions. In addition, the widespread adoption of liquid biopsies in cancer diagnostics and the increasing utilization of NGS technologies to introduce non-invasive cancer biomarkers for real-time cancer monitoring and detection are creating a positive market outlook. In line with this, continuous technological innovations in sequencers, such as the integration of cloud-computing systems for enhanced data security and management, are strengthening the market growth. Apart from this, continuous financing by governments of various countries to improve healthcare infrastructure is providing a thrust to the market growth. Furthermore, increasing investments by leading players in research and development (R&D) activities for molecular biology, technical engineering, and sequencing chemistry is offering a favorable market outlook.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global next-generation sequencing (NGS) market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on sequencing type, product type, technology, application and end-user.
Breakup by Sequencing Type:
Whole Genome Sequencing
Targeted Resequencing
Whole Exome Sequencing
RNA Sequencing
CHIP Sequencing
De Novo Sequencing
Methyl Sequencing
Others
Targeted resequencing represents the largest market segment due to the presence of numerous companies in the NGS market offering targeted resequencing services.
Breakup by Product Type:
Instruments
Reagents and Consumables
Software and Services
Reagents and consumables represent the most commonly used product type that assists in sample preparation, DNA isolation, sample cleanup, target enrichment, and quality assurance.
Breakup by Technology:
Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-Molecule Real-Time Sequencing
Nanopore Sequencing
Others
Sequencing by synthesis finds extensive applications on account of its high accuracy in performing DNA sequencing and its growing incorporation in NGS instrumentation. In addition, it offers the highest yield of error-free throughput results.
Breakup by Application:
Biomarker and Cancer
Drug Discovery and Personalized Medicine
Genetic Screening
Diagnostics
Agriculture and Animal Research
Others
Biomarker and cancer currently dominate the market due to the rising prevalence of cancer and increasing awareness among individuals about the benefits of early diagnosis and treatment.
Breakup by End-User:
Academic Institutes & Research Centers
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Others
Academic institutes and research centers account for the majority of the market share due to the increasing application of NGS solutions in research projects.
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market due to the availability of a technologically advanced healthcare research framework in the region, coupled with the presence of multiple clinical laboratories that employ NGS to provide genetic testing services.
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Becton Dickinson and Company, 10x Genomics, BGI Group, Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina Inc., Genewiz, Macrogen, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, Thermo Fisher Scientific, Qiagen N.V., GenapSys Inc., etc.
Key Questions Answered in This Report
- 1. What was the size of the global next-generation sequencing (NGS) market in 2023?
- 2. What is the expected growth rate of the global next-generation sequencing (NGS) market during 2024-2032?
- 3. What are the key factors driving the global next-generation sequencing (NGS) market?
- 4. What has been the impact of COVID-19 on the global next-generation sequencing (NGS) market?
- 5. What is the breakup of the global next-generation sequencing (NGS) market based on the sequencing type?
- 6. What is the breakup of the global next-generation sequencing (NGS) market based on the product type?
- 7. What is the breakup of the global next-generation sequencing (NGS) market based on the technology?
- 8. What is the breakup of the global next-generation sequencing (NGS) market based on the application?
- 9. What is the breakup of the global next-generation sequencing (NGS) market based on the end- user?
- 10. What are the key regions in the global next-generation sequencing (NGS) market?
- 11. Who are the key players/companies in the global next-generation sequencing (NGS) market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Next-Generation Sequencing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Sequencing Type
- 6.1 Whole Genome Sequencing
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Targeted Resequencing
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Whole Exome Sequencing
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 RNA Sequencing
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 CHIP Sequencing
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 De Novo Sequencing
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Methyl Sequencing
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
7 Market Breakup by Product Type
- 7.1 Instruments
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Reagents and Consumables
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Software and Services
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Technology
- 8.1 Sequencing by Synthesis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ion Semiconductor Sequencing
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Single-Molecule Real-Time Sequencing
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Nanopore Sequencing
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Application
- 9.1 Biomarker and Cancer
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Drug Discovery and Personalized Medicine
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Genetic Screening
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Diagnostics
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Agriculture and Animal Research
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
- 9.6 Others
- 9.6.1 Market Trends
- 9.6.2 Market Forecast
10 Market Breakup by End-User
- 10.1 Academic Institutes & Research Centers
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Hospitals & Clinics
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Pharmaceutical & Biotechnology Companies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
- 10.4 Others
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.2 Asia Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
12 SWOT Analysis
- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
15 Price Indicators
16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 Agilent Technologies Inc.
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
- 16.3.2 Becton Dickinson and Company
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.2.3 Financials
- 16.3.2.4 SWOT Analysis
- 16.3.3 10x Genomics
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.4 BGI Group
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.5 Eurofins Scientific
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.6 F. Hoffmann-La Roche AG
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.7 Illumina Inc.
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 Financials
- 16.3.7.4 SWOT Analysis
- 16.3.8 Genewiz
- 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.9 Macrogen Inc.
- 16.3.9.1 Company Overview
- 16.3.9.2 Product Portfolio
- 16.3.9.3 Financials
- 16.3.10 Oxford Nanopore Technologies
- 16.3.10.1 Company Overview
- 16.3.10.2 Product Portfolio
- 16.3.10.3 Financials
- 16.3.10.4 SWOT Analysis
- 16.3.11 Pacific Biosciences
- 16.3.11.1 Company Overview
- 16.3.11.2 Product Portfolio
- 16.3.11.3 Financials
- 16.3.12 Perkinelmer Inc.
- 16.3.12.1 Company Overview
- 16.3.12.2 Product Portfolio
- 16.3.12.3 Financials
- 16.3.12.4 SWOT Analysis
- 16.3.13 Thermo Fisher Scientific Inc.
- 16.3.13.1 Company Overview
- 16.3.13.2 Product Portfolio
- 16.3.13.3 Financials
- 16.3.13.4 SWOT Analysis
- 16.3.14 Qiagen N.V.
- 16.3.14.1 Company Overview
- 16.3.14.2 Product Portfolio
- 16.3.14.3 Financials
- 16.3.14.4 SWOT Analysis
- 16.3.15 Genapsys Inc.
- 16.3.15.1 Company Overview
- 16.3.15.2 Product Portfolio